Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Madison Mid Cap Fund Haruki Toyama, Andy Romanowich, Rich Eisinger | “Revvity ($RVTY) is a specialized life science tools and diagnostic testing company providing research informatics software, preclinical discovery reagents, and clinical diagnostic systems. Madison initiated a 2.28% position during the quarter, viewing the company as an attractively priced compounder that performed well as biopharma customer ordering activity resumed and AI enhancements improved end-market laboratory workflows. The investment rationale rests on Revvity's high proportion of recurring revenue and pricing power following its extensive portfolio transformation orchestrated by management away from commodity exposure. The company holds dominant niche economic moats in newborn screening diagnostics and discovery workflows, which generate sticky consumable demand and high gross margins. Madison notes that the business offers substantial operating leverage as biopharma spending rebounds, representing growth and profitability that remain underappreciated in the stock's current valuation multiple. Catalysts include biopharmaceutical research and development budget normalizations, diagnostic menu expansion, and cross-selling across its research informatics suite. The primary risks involve cyclical biotech venture funding volatility, diagnostic reimbursement headwinds, and integration risks surrounding newly aligned platforms.” | BULL | Q3 2026 Oct 12, 2026 | View Pitch |
Sycamore Mid Cap Value Equity Gary H. Miller | “Shares declined due to negative sentiment surrounding conservative government and academic research funding. However, the company remains fundamentally strong and positioned to benefit from a recovery in biotech funding and pharmaceutical deals.” | BULL | Q1 2026 Mar 31, 2026 | View Pitch |
Bretton Fund Stephen Dodson and Raphael de Balmann | “Revvity We invested in the former PerkinElmer in the wake of Covid. In many ways we are in a new golden age for medicine—the growth of biologics and peptides, new frontiers in personalized medicine, AI to identify actionable therapies, mRNA to deliver them—and Revvity, which makes the consumables used in both research facilities and customer- facing diagnostics, seemed like a good platform. Unfortunately, management spent its Covid testing windfall on overpriced acquisitions while divesting its cash-generative but less exciting food testing division, and then was left flat-footed when pharma research spending stalled and the FDA dramatically reduced science spending. Our overall return was -28.5%, or a -5.90% IRR, but the most painful loss was our opportunity cost. BSD Analysis: Revvity has successfully pivoted into a high-growth pure-play in the diagnostics and life sciences research markets. The company's focus on high-margin automated workflows and specialized genomic testing is beginning to yield fruit, evidenced by a strong pipeline and positive earnings revisions. While academic research funding has shown some global softness, Revvity's diagnostics segment remains a robust driver of recurring revenue and free cash flow. Management's recent approval of a significant share buyback program signals confidence in the stock's intrinsic value and its long-term growth trajectory. As healthcare systems increasingly move toward personalized medicine and early disease detection, Revvity is well-positioned to capture increasing demand for its innovative health science solutions.” | BEAR | Q4 2025 Feb 12, 2026 | View Pitch |
Bretton Fund Stephen Dodson and Raphael de Balmann | “Revvity successfully restructured post-pandemic by divesting lower-margin assets to build specialized diagnostic and research reagent franchises. The company trades at reasonable earnings multiples while maintaining market leadership across newborn screening and immunodiagnostics.” | BULL | Q4 2024 Dec 31, 2024 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.